Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981940 · ClinicalTrials.gov registry record · Phase 2
A Study of Abemaciclib in Recurrent Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT02981940: Active Phase 2 study of Glioblastoma, sponsored by Dana-Farber Cancer Institute.
NCT02981940 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (59% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02981940, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
Primary Outcome
Intratumoral abemaciclib concentration defined as the mean tumor-to-plasma ratio in contrast enhancing tissue. Patients were treated with abemaciclib prior to surgery. Tissue and plasma for analysis of this endpoint were obtained at the time of surgery.
Conditions Studied
Interventions
- DRUG Abemaciclib
- PROCEDURE Surgery
Study Locations (7)
California
- University of California Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- UT, M.D. Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT02981940 still lists
NCT02981940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.
NCT02981940 lists 7 locations in 5 states (California, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT02981940 about?
NCT02981940 is a clinical study titled "A Study of Abemaciclib in Recurrent Glioblastoma". This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
What is the current status of trial NCT02981940?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-02-09. Estimated completion is 2026-06-30.
What conditions does trial NCT02981940 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02981940?
The interventions under investigation include: Abemaciclib (DRUG), Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02981940?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02981940 being conducted?
This trial has 7 study locations across California, Massachusetts, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02981940's enrollment target sits among peer trials
45 97th of 199 higher than 101 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI